NCT05749588 2026-04-16
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Fudan University
Phase 2 Recruiting
Clinical Trials
8 trialsNCT07530094 2026-04-15
STELLAR01
Jiangsu Cancer Institute & Hospital
Phase 2 Recruiting
NCT07527026 2026-04-14
A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer
Chinese PLA General Hospital
Phase 2 Recruiting
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT07320586 2026-03-13
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Shandong Tumor Hospital
Phase 2 Recruiting
NCT06239727 2026-03-06
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Sun Yat-sen University
Phase 3 Recruiting
NCT05139095 2026-02-05
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT04342910 2026-01-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting